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Abstract 
The repair of organs and tissues has stepped into a prospective era of regenerative medicine. However, basic research 
and clinical practice in the lung regeneration remains crawling. Owing to the complicated three dimensional struc-
tures and above 40 types of pulmonary cells, the regeneration of lung tissues becomes a great challenge. Compelling 
evidence has showed that distinct populations of intrapulmonary and extrapulmonary stem/progenitor cells can 
regenerate epithelia as well as endothelia in various parts of the respiratory tract. Recently, the discovery of human 
lung stem cells and their relevant studies has opened the door of hope again, which might put us on the path to 
repair our injured body parts, lungs on demand. Herein, we emphasized the role of endogenous and exogenous 
stem/progenitor cells in lungs as well as artificial tissue repair for the injured lungs, which constitute a marvelous 
toolbox for the treatment of acute lung injury. Finally, we further discussed the potential problems in the pulmonary 
remodeling and regeneration.
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Background
With the occurrence and evolution of critical diseases 
(trauma, burn, infections, sepsis, hemorrhagic shock), 
lungs belong to the most easily injured organs. Acute 
lung injury (ALI) also constitutes the causative factor for 
the other organ chaos [1]. Thus, it is important to prevent 
and cure the respiratory dysfunction for the improvement 
of treatment in multiple organ dysfunctions (MODS) [2]. 
However, compelling evidence indicates that the remedy 
of ALI and acute respiratory distress syndrome (ARDS) 
based on the ventilation function support and anti-
inflammatory treatment remains unsatisfied [3–5]. Actu-
ally, the key point to treat the ALI and ARDS is to realize 
both the structural remodeling and functional repair, and 
recover the normal gas exchange. Presently, the potential 
measures to realize the repair and regeneration of injured 
adult lung tissues is to activate the self repairing potential 
through an extra- or intra-pulmonary route [6, 7], and 
improve the local pulmonary microenvironment so as to 
promote the reconstruction of breathing function. Dur-
ing these complex courses, the principal biological event 
is that stem/progenitor cells are synergistically involved 
in the repair of injured lung tissues (Fig. 1).
Review
Stem/progenitor cells outside the lungs
Mobilization of stem/progenitor cells in bone marrow
Bone marrow is the largest pool for the storing of stem 
cells, which constitutes the principal source of stem/
progenitor cells outside the lungs. The potential repair-
ing cells include bone marrow derived mesenchymal 
cells (BMSCs), epithelial progenitor cells (EPCs) and 
hematopoietic stem/progenitor cells (HSPCs) [8]. During 
acute injury, infections or the mobilizers’ administration, 
they egress from the bone marrow pool and may direc-
tionally migrate towards the injured lung tissues under 
the guidance of chemokines. Finally, they are involved 
in the repairing courses in the differentiated cell types 
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(G-CSF) is known to induce mobilization of BMSCs to 
peripheral blood, while their increased homing to sites 
of injury would improve tissue healing. Also, the mobi-
lizers could induce the increase of bone marrow-derived 
EPCs in the murine model of emphysema [10], inducing 
angiogenesis in injured lungs through mobilizing EPC 
[11]. Similarly, in the patients suffered from bacteria 
pneumonia and ALI, the number of circulating EPCs is 
obviously increased, which is even related to their prog-
nosis. In turn, the mobilizing capacity of bone marrow-
derived EPCs is impaired after ARDS [12], indicating 
the necessity of improvement of bone marrow mobiliza-
tion so as to promote the pulmonary repair. Meanwhile, 
mobilization of HSPCs and colony formation capacity of 
peripheral blood mononuclear cells demonstrated great 
significance after ALI [13–15]. All these findings indicate 
Fig. 1 Schematic illustration of the exogenous and endogenous stem/progenitor cells as well as the regular delivery routes in the repair and regen-
eration in acute lung injury
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that the bone marrow-derived stem/progenitor cells 
exhibit the mobilizing courses, and play a substantial role 
in the regression of excessive inflammatory responses 
and repair in injured lungs. In addition, recent research-
ers found that ALI with endotoxin or NO2 does not 
enhance development of airway epithelium from bone 
marrow [16], suggesting that the expansion and prolifera-
tion of endogenous bone marrow-derived stem/progeni-
tor cells toward airway descendants are further required 
once their mobilization occurs.
Engraftment of stem/progenitor cells in bone marrow 
and peripheral blood
Presently in the clinical stem cell therapy, mesenchy-
mal stem cells (MSCs) are widely used owing to the easy 
accessibility and low immunogenicity [17]. The allograft 
of bone marrow MSCs are easily tolerated for the accep-
tors due to the low expression of major histocompat-
ibility complex (MHC) I, II and co-stimulator molecules 
in T cells. Thus, these theoretically reasonable cells are 
further stored until use without ethical disputation. In 
recent years above 130 clinical trials of MSCs have been 
registered and carried out. Bone marrow MSCs have 
been proved to efficiently alleviate the lung injury and 
promote the recovery courses [18], partly due to the 
immunoregulatory effects [19, 20]. Meanwhile, adminis-
tration of MSCs via the vein or trachea also reduces the 
LPS-induced ALI, alleviating the chest impact injury and 
hyperoxia-induced lung injury, reversing the pathologi-
cal reduction of pulmonary surface area and the blunted 
breathing function in rodents [21, 22]. Bleomycin-
induced inflammation, collagen deposition and fibrosis 
were also attenuated after the MSCs injection [10]. The 
conditioned medium for MSCs culture further showed 
similar therapeutic effects on pulmonary function [23]. 
Hence, bone marrows MSCs possess the prospective 
clinical value for the repair and regeneration in ALI.
Concerning the protective roles of bone marrow- and 
peripheral blood-derived EPCs in ALI, recent studies 
showed that their peripheral infusion could lead to hom-
ing in injured lung tissues [24], relieving the inflamma-
tory injury [25, 26] and promote the endothelial repair 
and recovery of immune function dissonance [26, 27], 
which may be enhanced by the treatment of simvas-
tatin [28]. Also, inhaled NO contributes to the repair 
of injured lungs in piglets via increasing circulating 
endothelial progenitor cells [29]. The number of EPCs is 
positively related to the animal survival. From the clini-
cal point of view, the increased number of EPCs in the 
pneumonia patients is the innocent representation of 
self repair in bodies. If the number of circulating EPCs 
didn’t increase in ALI [12], these patients might have 
distressing outcome, indicating the great necessity for 
supplementing the EPCs in combination with immune 
modulatory measures.
Presently, the understanding of HSPCs efficacy in ALI 
remains limited. Interestingly, stem/progenitor cells 
derived from the circulation contribute to the repair of 
injured lungs in surgically generated parabiotic mice [30], 
indicating the potential contribution of HSPC in ALI. In 
fact, during the human prenatal development, the HSPCs 
firstly appear in the fetal yolk sac. Four months later. 
They transfer to the fetal livers for the further growth and 
differentiation. In the newborn phase, they finally locate 
in the bone marrow, followed with the appearance of 
varying stages of leukocytes, red cells and platelets. Thus, 
the role of HSPCs at least includes the immunoregulatory 
and repairing effects in ALI.
Engraftment of adipose‑derived stem cells (ADSCs)
Since the discovery of ADSCs by Zuk et  al. [31], their 
capacity in the repair and regeneration of injured lungs 
has been widely investigated. ADSCs exhibit large reserve 
quantity owing to the extensively distributed adipose tis-
sues in bodies. As compared with the BMSCs, ADSCs 
were easily harvested from dumped adipose end product 
via the regular adipose aspiration technique. The total 
volume of adult bone marrow extracts is 40 ml while that 
of adult adipose can easily reach 500  ml. Moreover, the 
harvest of ADSCs is easy to adopt as well as no potential 
blood-derived contamination and immunologic rejection 
compared with the bone marrow allograft [32]. The pick-
up rate of ADSCs is 100–500 times of that of bone mar-
row MSCs. So, ADSCs can be abundantly harvested in 
the limited time without in vitro expansion.
In a randomized, placebo-controlled pilot study, 
ADSCs showed significant protective effects on ALI. 
Optical imaging analysis further indicated that they 
promote the subacute airway remodeling, and ame-
liorates ventilator-induced lung injury in rats [33, 34]. 
The main protective reasons referred to eNOS and 
eNOS-derived NO [35]. Actually, ADSCs could secrete 
vascular endothelial growth factor, granulocyte colony-
stimulating factor (G-CSF), hepatocyte growth factor 
(HGF), stromal derived factor-1 (SDF-1) when promot-
ing the angiogenesis. Also, they release collagen I and 
III and laminin via a paracrine route [32, 36]. All these 
factors may play a substantial role in pulmonary struc-
tural repair and functional reconstruction in ALI.
Engraftment of placenta‑derived stem/progenitor cells
Placenta-derived stem/progenitor cells come from 
placenta, umbilical cord and amniotic fluid and their 
contents. Among them, the placenta is structurally com-
plicated. Human placenta consists of amnion, chorion 
and basal deciduas. The amnion and chorion are from 
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fetus while basal deciduas are from precursor. The pla-
centa is the reservoir of stem and progenitor cells during 
the fetal development. Once the fetal disengagement is 
finished, it is easily acquired without ethical disputation. 
Presently, placenta-derived stem/progenitor cells are 
positively involved in the repair of injured lungs includ-
ing fetal membrane-derived MSCs, umbilical cord MSCs, 
umbilical cord blood-derived MSCs, amniotic fluid stem 
cells, and amnion epithelial cells, etc. [37].
Previous studies have demonstrated that amniotic fluid 
stem cells could attenuate hyperoxia-induced ALI in mice 
[38], inhibiting the progression of bleomycin-induced 
pulmonary fibrosis via CCL2 modulation in bronchoal-
veolar lavage [39]. Amnion epithelial cells could also act 
as a seed cells for the therapy of ALI [40]. Meanwhile, 
Human umbilical cord MSCs reduced systemic inflam-
mation and attenuated LPS-induced ALI in rats [41]. 
Human CD34+ progenitor cells from umbilical cord 
blood could also attenuate inflammatory lung injury fol-
lowing LPS challenge [42]. Further, intratracheal admin-
istration of umbilical cord blood-derived MSCs played a 
pleasing role for the patient with ARDS [43]. Therefore, 
placenta-derived stem/progenitor cells act as efficient 
candidates for the treatment of ALI.
Engraftment of embryo‑derived stem/progenitor cells
Human embryonic stem cell-derived progenitor cells 
could ameliorate sepsis-induced lung inflammatory 
injury via interaction with a specific population of with 
CD11b+ cells [44]. Meanwhile, researchers could get 
functional airway epithelium from human embryonic 
stem cells through an expansive generation measure [45]. 
However, owing to the ethical bottleneck and law dis-
putation, they shouldn’t be recommended to be an ideal 
seed cells in the repair and regeneration of injured lungs.
Engraftment of genetically engineered stem cells
Induced pluripotent stem cells (iPSCs) were firstly 
acquired from genetically engineered fibroblasts in skin, 
similar to the dedifferentiation findings by Fu, et al. [46] 
in 2001. Now, it has been confirmed that ADSCs are 
easier to be transferred to iPSCs than fibroblasts [47]. 
The embryonic stem cell-like functions of iPSCs were 
proved occasionally since 2007. iPSCs were also got from 
a patient with ALI [48], which could differentiate into 
alveolar epithelial cells in  vitro for use in  vivo [49]. The 
therapeutic capacity of iPSCs might be related to the 
inhibition of Src, NF-κB and PI3K/Akt pathway as well as 
IP-10-dependent paracrine regulation [50–52]. In view of 
the initialization characteristics of iPSCs from adult cells, 
they could pave the way to the structural remodeling 
and functional repair in ALI without any ethical and law 
obstacles.
Meanwhile, stem/progenitor cells were widely used to 
act as the vectors of target genes to attenuate the inflam-
matory injury and promote the repair and regeneration 
of injured lung. Recent studies have demonstrated that 
the genetically engineered stem cells with overexpres-
sion of CXCR4 [53], angiotensin-converting enzyme 2 
[54], IL-33 antagonist soluble IL-1 receptor-like-1 [55], 
keratinocyte growth factor, angiopoietin 1 [56] and 
dominant-negative inhibitor of CCL2 [57] could greatly 
facilitate treatment of ALI in rodents. All these results 
substantially indicate that the therapeutic efficacy of 
genetically engineered stem/progenitor cells boosted 
by the stably transfected target genes in the pulmonary 
repair.
Stem/progenitor cells in the lungs
In the adult mammalian tissues and organs, there are still 
some endogenous stem/progenitor cells, which distribute 
the predetermined microenvironment named niche. The 
niche supplies the repairing cells for the homeostasis and 
repair of tissues and organs. Concerning the endogenous 
pulmonary stem/progenitor cells, researchers reported 
that they exist in the adult respiratory tissues in rodents 
and humans (Table 1). Although there remains lack of the 
specific molecular markers for the lung stem/progenitor 
cells, their isolation and culture seems difficult, and the 
classification of these cells is also in controversial, they 
have been widely approved for the maintaining of pulmo-
nary structural stability and functional repair.
Pulmonary stem/progenitor cells in the respiratory tract
Pulmonary stem/progenitor cells (trachea and bronchial 
stem cells, bronchiolar stem cells, bronchioloalveolar 
stem cells, alveolar stem cells and alveolar type II cells, 
etc.) were shown to play substantial roles for the recov-
ery of homeostasis and repair of injured tissues through 
molecular markers, lineage tracing and clonal analysis 
[58–63] (Fig. 2). The alveolar epithelium is composed of 
the flat alveolar type I (AT1) cells comprising 95 % of the 
gas-exchange surface area and less than 5 % of cuboidal 
alveolar type II (AT2) cells comprising the rest. Once ALI 
occurs, AT1 cells showed injury, necrosis or apoptosis. 
Then, rare, long-lived, mature AT2 cells could differen-
tiate and substitute the disabled AT1 cells in the injured 
area [64, 65]. At this moment, some of AT2 cells were 
found to become hypertrophy, which is easily discrimi-
nated in various injured lung tissues. Meanwhile, the 
heterogeneity of AT2 cells had been presented and classi-
fied with three subgroups including the alveolar renewal 
focus, alveolar repair focus and AT2 replacement focus 
[66]. Further, the subgroup of stem cells were shown to 
exist within the AT2 cells, which were found to widely 
distribute in the terminal bronchiole, bronchioalveolar 
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Table 1 Role of main stem/progenitor cells in the regeneration/repair after acute lung injury




Trachea, bronchi Basal cell Activation Differentiation toward goblet cells, 
ciliated cells, mucous cells and 
serous cells
[61]
Trachea Duct cell Activation Differentiation toward goblet cells, 
ciliated cells, mucous cells, serous 
cells and myoepithelial cells
[62, 63]
Bronchiole Clara cell Activation Differentiation toward ciliated, AT1 
and AT2 cells




Variant Clara cell Activation Differentiation toward cilia cells, 






Activation Differentiation toward bronchiolar 
Clara cells and alveolar cells
[72, 98]
Mesenchymal Mesenchymal stem cell, 
stromal cell
Activation Bronchioalveolar stem cells increase, 
preservation of epithelial perme-





Human lung stem cell Activation Differentiation toward Alveolar and 
endothelia cells
[81]
Alveolus Alveolar type II cells Activation Differentiation toward Alveolar type I 
cells and BASC
[64, 65, 69]
Alveolus AEPC Activation Differentiation toward Alveolar type 





Bone marrow Mesenchymal stem cell Mobilization, isolation Bacteria clearance, anti-inflamma-
tion, tissue repair
[9]
Epithelial progenitor cell Mobilization, isolation Anti-inflammation, tissue repair [10]
Hematopoietic stem/
progenitor cell
Mobilization, isolation Anti-inflammation, tissue repair [14, 15]
Placenta Amniotic fluid stem cells Isolation Anti-inflammation, tissue repair [38, 39]
Amnion epithelial cells Isolation Anti-inflammation, tissue repair [40]
Umbilical cord CD34+ 
progenitor cells
Isolation Anti-inflammation, tissue repair [42]
Umbilical cord mesen-
chymal stem cells




Isolation Anti-inflammation, tissue repair [37]
Adipose Mesenchymal stem cell Isolation Anti-inflammation through eNOS 
and eNOS-derived NO, tissue repair
[34–36]





Isolation Anti-inflammation, tissue repair [44]
Blood Mesenchymal stem cell Isolation Anti-inflammation, tissue repair [43]
Epithelial progenitor cell Isolation Anti-inflammation, tissue repair [12]
Hematopoietic stem/
progenitor cell
Isolation Anti-inflammation, tissue repair [14]
Engineering stem/
progenitor cell
iPSCs Isolation and genetic 
manipulation
Anti-inflammation via NF-KB and Src 





Isolation and genetic 
manipulation
Anti-inflammation, tissue repair [53, 54, 56]
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duct junction (BADJ) and alveolus. In comparison, the 
contribution of AT2 cells is more significant than bron-
chioalveolar stem cells (BASCs) concerning the numeri-
cal preponderance and differentiation potential [67, 68]. 
Some murine AT2 cells can also generate BASCs unex-
pectedly [69]. Therefore, during the course of pulmonary 
remodeling after ALI, the efficient shift of repair poten-
tial in AT2 cells including the number, distribution and 
cellular transfer path should be undoubtedly weighted.
The endogenous stem cells in the resident lung cells 
were further confirmed using the GFP-labeled chimera 
mice, which synergistically contribute to the regenera-
tive alveolus. Robust preclinical literature has showed 
that AT2 cells could repair the injured alveolar epithe-
lium. However, the potential of pulmonary endogenous 
stem cells to substituting the injured AT2 cells remains 
unclear. To address this question, new findings sug-
gested that the murine stem cell antigen (Sca)-1 positive 
cell may be the endogenous lung stem cell although it 
could not found in rats [70]. The cell number with stem 
cell marker (Sca-1, CD34 and c-kit) increased in the 
elastase-induced lung injury. The combination of HGF 
and elastase could synergistically increase the number 
of Sca-1+/SPC+ cells. Most of the Sca-1+ belong to 
the endogenous lung stem cells while most of the c-kit+ 
cells come from the bone marrow [70, 71]. Therefore, 
the increase in the number of endogenous lung stem/
progenitor cells is in great need for the repair of injured 
lung tissues. In recent years, Zhang and colleagues [72] 
found that the excitation of Wnt signal pathway could 
significantly increase the number of BASCs. The phar-
macological modulators, lithium may also promote the 
amplification and differentiation of specific stem cell 
group in the lung tissues [73], which supplies the new 
avenue for the endogenous repair of injured lungs on the 
basis of pulmonary stem cells.
Clara cells possess anti-inflammatory capacity and 
impacts the pulmonary innate immune response [74, 75]. 
Conditional depletion of Clara cells induced peribron-
chiolar fibrosis, and potentiated lung inflammation and 
alveolar dysfunction, demonstrating its role of functional 
repair/regeneration in ALI [76]. Concurrently, our stud-
ies further showed that the boosted expression of Clara 
cells resulted in the transformation of cellular shape 
from sporadic cube to serried high prismatical, and the 
enhancement of anti-inflammatory effect of Clara cell 
secreting protein (CCSP) after retinoic acid plus simvas-
tatin treatment in shock-endotoxin-induced pulmonary 
damage [77]. CCSP, an important lung derived protective 
factor, may play a substantial role on the pathogenesis of 
ALI induced by Endotoxemia [78]. Moreover, compel-
ling evidence showed that the differentiation potential 
of Clara cells towards AT1 and AT2 cells after severe 
lung injury [79, 80]. So, the improved AT1 and AT2 cells 
maybe partly derived from facultative Clara cells so as to 
keep the integrity of alveolar walls.
New family members for pulmonary stem/progenitor cells: 
human lung stem and alveolar progenitor cells
Presently, as compared with the boosting of murine lung 
stem cells, the investigation of human lung stem cells 
(HLSCs) remains superficial since their presentation by 
Kajstura et al in 2011 [81]. The main reasons are as fol-
lows. First, there remains lack of the specific markers for 
HLSC. Second, the acquisition of human lung tissues is 
limited. Nonetheless, the HLSCs researches proved their 
in vitro c-kit positive characteristics, which were further 
confirmed using the in  vivo experimental models. Also, 
some experimental preparations have been given for the 
potential clinical usage. But it remains a long way to go 
before the clinical engraftment for HLSCs. First, how 
efficient is the HLSCs engraftment. Whether does the 
newborn lung tissues differentiated from HLSCs possess 
the normal physiological function? Second, how is the 
Fig. 2 Distribution of the representative stem/progenitor cells in 
lungs
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feasibility of HLSCs engraftment? For the patients suf-
fered from the lung diseases, whether their HLSCs lose 
the self proliferative and multidirectional differentiation 
capacity owing to the infaust pulmonary microenviron-
ment? Third, whether does the variant engraftment of 
HLSCs has the same therapeutic effect compared with 
their auto transplantation? Finally, there remains a series 
of technique bottle neck from their isolation and culture 
to engraftment.
Meanwhile, recent studies further acquired human 
alveolar progenitor cells (AEPCs) [82], AEPCs have the 
endothelial phenotype with MSCs character. By using 
the chip analysis, AEPCs were found to share many genes 
with MSCs and AT2 cells, indicating the phenotype over-
lapping between alveolar epithelial cells and MSCs. In 
fact, APECs possess the capacity of phenotypic conver-
sion between the mesenchymal and epithelium, indicat-
ing their potential in the pulmonary tissue repair. The 
mesenchymal characteristics, especially anti-apoptotic 
ability may benefit the functional epithelial progenitor 
cells. Further investigation is necessary to elucidate their 
detailed pathophysiological role in the repair of injured 
lungs.
MSCs in the lungs
The lung MSCs have the ability of self renewal and differ-
entiate into mesenchymal cell. Given the varying charac-
teristics in the different organs, the basic criteria for lung 
MSCs include the adhesive ability on the plastic petri 
dishes, and the in vitro ability of osteogenesis, adipogen-
esis and cartilagenesis [22] since there are no specific cel-
lular markers on the surface of pulmonary MSCs.
The lung MSCs can be isolated from the lung and bron-
choalveolar lavage fluid. Karoubi et  al. [83] isolated the 
MSCs from the human lung tissues in the surgical opera-
tion, and successfully induced their differentiation toward 
the AT2 cells expressing AQP5 and CCSP. Although the 
action of MSCs is not completely clear in the lung regen-
eration, the beneficial effects of MSCs on the lung inju-
ries have been extensively investigated. MSCs can secrete 
diverse cytokines and growth factors. Co-culture of 
LPS-stimulated lung cells and MSCs could result in the 
reduction of pro-inflammatory cytokines, indicating that 
the soluble mediators may inhibit excessive inflamma-
tory responses, or the direct interactions of lung cells and 
MSCs could produce the anti-inflammatory effects. Simi-
lar results have showed that the immunoregulatory role 
of MSCs on immune cells (T cells, B cells and NK cells). 
Other studies reported that the intra trachea adminis-
tration of pulmonary stem cells with the MSCs pheno-
type attenuated the elastase-induced emphysema [84]. 
The transplanted stem cells can reach the alveolar space 
besides some of them reserved in the alveolar wall. These 
results didn’t support the idea of cell differentiation, but 
indicated their immunoregulatory effects in the injured 
lung tissues. In addition, new mechanisms included the 
mitochondria DNA transmission between the MSCs 
and other cytosolic components through intercellular 
bridges, which may regulate the cellular biological ability 
in the recipient cells [85]. Hence, the protective effects of 
MSCs are rather the anti-inflammatory effects than the 
differentiation towards the lung cells.
Mechanisms of repair and regeneration by stem/progenitor 
cells in ALI
The protective role of stem/progenitor cells is to release 
the anti-injured and pro-reparative factors mainly via the 
paracrine/endocrine pathways, which is primarily due 
to their significant apoptosis and clearance by unknown 
innate immune mechanisms after their transplantation. 
Likewise, the researches concerning their microenviron-
ment regulation demonstrated that the stem/progenitor 
cell-derived conditioned medium possesses the simi-
lar efficacy, suggesting that the secreting factors (IL-10, 
IL-RN, VEGF, angiopoietin-1) act as the anti-inflamma-
tory and pro-reparative mediators on the gas-blood bar-
rier in ALI [86–89]. Moreover, microvesicles containing 
anti-inflammatory mRNA and miRNA secreted by the 
stem/progenitor cells also possessed the therapeutic 
potential during the repairing courses [90–92]. Second, 
BMSC could protect against oxidative stress in Escheri-
chia coli-induced ALI in mice [93], and ameliorate sea-
water-exposure-induced ALI by inhibiting autophagy 
in lung tissues [94]. Concurrently, they could restore 
sodium transport and preserve epithelial permeability 
in an in  vitro model of acute alveolar injury [95]. Third, 
BMSC could reduce inflammation while enhancing bacte-
rial clearance in bacterial pneumonia [96, 97]. Fourth, the 
number of a population of Clara cells possessing secret-
ing capacity; named bronchioalveolar stem cells (BASCs) 
were increased in ALI [98]. The ex vivo colony formation 
experiments proved that the proliferation of BASCs was 
maybe due to MSCs but not growth factors. The thera-
peutic effect of MSCs on the chronic bronchopulmonary 
dysplasia showed that BASCs help the reconstruction of 
pulmonary epithelial structure. So, the repairing effects of 
MSCs maybe realize via the stimulation of BASCs prolif-
eration, demonstrating the peculiarly promoting effects of 
extra pulmonary stem cells on the lung stem cells during 
the repair and regeneration.
Influencing factors of stem/progenitor cells in the lung 
repair and regeneration
Etiology in ALI
The previous cell therapy on ALI showed that the time 
courses of pulmonary remodeling and functional repair 
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varies depending on the wound agents (live bacteria, 
oleic acid, bleomysin, etc.) [99], indicating the clinical 
therapeutic efficacy may be intrinsically related to the 
ALI etiology. Thus, it is important to make the sensible 
selection and stringent judgment for the initiating fac-
tors, contaminated pathogens (bacteria, virus, and fun-
gus) and potential window phases in the stem/progenitor 
cell-mediated lung repair.
Concordance in neuroendocrine immune network
The injured lungs may release large quantities of stress-
related neuroendocrine hormones, neuromediators and 
neuropeptides [100–102], which deeply influence the 
biological activities of stem/progenitor cells. Steadily 
growing evidence has been shown that glucocorticoids, 
epinephrine and norepinephrine may be involved in the 
migrating or chemotaxis activities during the mobilizing 
courses [103]. Acetylcholine released via vagus nerve and 
postganglionic neurons of adrenergic nerve has also been 
proved to modulate these courses [104]. Recently, mela-
tonin treatment was found to improve ADSCs therapy 
for acute lung ischemia–reperfusion injury [105]. Con-
currently, the immune status are also related to the pro-
tective efficacy of MSCs because they could reduce lung 
injury in immunocompromised but not immunocompe-
tent mice [106]. Thus, the consonance of neuroendocrine 
immune network is of great importance for the lung 
repair and regeneration.
Source of stem/progenitor cells in the lung repair 
and regeneration
The cell therapy of ALI suggested that the prominent 
advantage of exogenous stem/progenitor cells is quan-
tity-controllable although the procedures of harvest, 
purification and expansion are required in most con-
ditions. Hence, the potential contamination and bio-
safety should be carefully considered (Table  2). Once 
the transplantation procedure is completed, the turno-
ver of these stem/progenitor cells should also be further 
controlled to lower the risk of graft rejection and tera-
toma formation [107–109]. In comparison, the greatest 
advantage of endogenous stem/progenitor cells lies in 
the good safety only required to use the mobilizers or 
activating elements for their redistribution within the 
bone marrow, blood and lungs. However, the constraint 
of cell numbers especially in the blunted mobilization 
responses for some patients may deteriorate the thera-
peutic efficacy. In addition, other important findings 
have reported that there exist some differences between 
MSCs from bone marrow, placenta and umbilical cord 
blood in terms of their immunosuppressive properties 
against T cells [110].
Species, age and delivery routes in stem/progenitor cells
First, The stem/progenitor cells in the same species is 
better than in the different species in the ALI therapy 
[111]. Likewise, the autotransplantation is preferen-
tially selected compared with allotransplantation. Sec-
ond, aging stem/progenitor cells were showed to have 
impaired migration and anti-inflammatory responses as 
well as abnormal immunosuppressive properties against 
T cells [110, 112], indicating the selection of young stem/
progenitor cells is in preference. Third, the delivery 
routes for stem/progenitor cell transplantation are also 
comparable. The therapeutic effects via intraperitoneal 
route were slightly inferior to intravenous route in ami-
odarone induced lung injury in rats [113]. So, the reason-
able transplantation route (venous, trachea, intrapleural 
or intraperitoneal pathway) should be carefully consid-
ered for the ideal therapeutic efficacy (Fig. 1).
Artificial tissue repair for the injured lungs
Until now, few lungs are available for transplantation 
and the results have not been completely assentient. 
Hence ways are being sought to either engraft stem/
progenitor cells or fetal lung cells that will form pulmo-
nary structures to the severely injured lungs, or build 
bio-artificial lungs that completely replace the depleted. 
However, owing to the complicated three-dimensional 
tissue structure and above 40 cell types, lungs are difficult 
to be artificially constructed perfectly. Recently, several 
artificial lung models have been presented. The essential 
researches utilized the scaffold material that supports 
the development of alveolar-like epithelia and endothe-
lia from fetal lung cells. Meanwhile, the decellularized 
lungs were also repopulated with fetal lung epithelial 
cells delivered via the trachea and lung endothelial or 
human umbilical cord vein cells through the pulmonary 
Table 2 Comparison of endogenous and exogenous stem/progenitor cells in the lung regeneration/repair








Exogenous stem  
progenitor cells
+ + + ± + + ±
Endogenous stem 
progenitor cells
− − − − + + −
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artery. The constructs were then cultured in a bioreac-
tor where the cells regenerated region-specific tissue 
with the characteristics of normal alveolar tissue before 
transplantation. Although these cells need to be care-
fully investigated before the clinical usage, the integrity of 
lung stroma remains to be resolved, and the gas exchange 
capacity is limited, the concept of bio-artificial lungs may 
supply a candidate replacement measure for the severe 
lung injury owing to its low immune rejection and con-
trolled organ origin, which might throw sunshine on the 
50 million end staged-patients with ALI.
Prospect and future directions
To the end, the endogenous lung remodeling, repair and 
regeneration has become the new avenue for the refrac-
tory lung diseases. However, the following concerns 
remains to be added. First, most of successful ALI experi-
ments were accomplished with rodents [114]. Their lungs 
in thoracic cavities possess the energetic proliferating 
capacity in the whole life period which is quite different 
from human lungs because the transplantation of exoge-
nous stem/progenitor cells into matured human lung tis-
sues seems difficult at least owing to our limited insight 
in the HLSC. But the initiation of endogenous stem/
progenitor (self renewal, proliferation, migration, and dif-
ferentiation) is safe and maybe efficient via some modu-
lators (KGF, HGF, retinoid acid, etc.). Second, in view of 
the bio-safety of endogenous stem/progenitor cells and 
the quantity constraint of exogenous stem/progenitor 
cells, it may be reasonable to consider the combination 
of these two types of cells in the ALI therapy. Third, the 
repair and regeneration of injured lungs is complicated. 
We should emphasize the microenvironmental regula-
tion via the neuroendocrine immune network [115, 116]. 
Only in this way may the stem/progenitor cells possess 
the ideal biological capability (migration, mobilization, 
chemotaxis and homing, expansion, differentiation and 
proliferation). Such good “soil” may benefit these “seed” 
cells in the remodeling and regeneration of injured lungs. 
Fourth, regarding the complicated cell types in lungs, the 
integration of inflammatory modulation and pro-repair 
factors’ increase may help inhibit their deleterious injury 
and promote the structural remodeling. The potential 
measures should consider the synergistic combination of 
statins plus retinoid acid, statins plus HGF, etc. Fifth, con-
cerning the stem/progenitor cell pool of the bone mar-
row, and the energetic reservoir of the stem/progenitor 
cell pool of placenta, umbilical cord and amnion during 
Fig. 3 Potential therapeutic strategy in endogenous repair responses in acute lung injury
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the perinatal period, the selection of compositive stem/
progenitor cell populations maybe benefit ALI treat-
ment more than a single stem/progenitor cell population, 
which has been partly confirmed by the previous stud-
ies of mononuclear cell populations in the bone marrow 
[117]. Sixth, concerning their robust protective capac-
ity via paracrine/endocrine mediators released by stem/
progenitor cells, it is valuable to develop some stem/pro-
genitor cell-derived therapeutic fluid similar to the con-
ditioned medium of stem/progenitor cell in combined 
with the microvesicles for the ALI therapy. Finally, from 
the previous experience in the research of bio-artificial 
lungs, it is valuable to deeply emphasize the contribution 
of extracellular matrix while using stem/progenitor cells, 
which might pave the road for the pulmonary integrity in 
the lung remodeling and regeneration (Fig. 3).
Conclusions
Taken together, the remaining unknown issues include the 
protraction regularity of lung stem/progenitor cell line-
age, the transition and turnover of extra pulmonary stem/
progenitor cell and the integration and docking between 
intra- and extra-pulmonary stem/progenitor cells. None-
theless, the ideal animal models, clinical samples as well 
as usage of intra- and extra-pulmonary stem/progenitor 
cells will undoubtedly contribute to the elucidation of 
pathophysiological mechanism of lung regeneration, and 
the pursuit of new measures for the refractory ALI.
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